CureVac Welcomes Two Members to its Supervisory Board
24 Giugno 2019 - 1:00PM
CureVac AG, a fully integrated biopharmaceutical company pioneering
the field of mRNA-based drugs, announced that Timothy Wright, M.D.
and Craig Tooman were elected as independent directors to CureVac’s
Supervisory Board at the Company’s Annual General Meeting.
These new members will support CureVac’s mission to use mRNA to
revolutionize human health with their vast drug development and
operational expertise. Their appointments increase CureVac’s
Supervisory Board from six to eight directors.
"We are pleased to welcome Tim Wright and Craig Tooman as new
Supervisory Board members," said Ingmar Hoerr, CureVac Co-Founder
& Supervisory Board Chairman. "Tim’s extensive
development experience and Craig’s executive and operational
involvement within the biotechnology industry mark important
additions to our team. As CureVac’s corporate operations and
mRNA-based pipeline grows internationally, we’re excited to add two
members with valuable U.S. experience to help us reach our
development goals.”
About the New Board Members
Timothy M. Wright, M.D. is currently a General Partner at TIME
BioVentures. Tim has deep knowledge in drug development from
early to late stage and has a track record in bringing numerous
drugs to market. He served as Chief Research and Development
Officer for Regulus Therapeutics from late 2016 - early 2019.
Prior to Regulus, he served as Executive Vice President,
Translational Science at California Institute for Biomedical
Research. From 2004-2014, Wright held positions of increasing
importance at Novartis and Novartis Institute for Biomedical
Research, culminating as Global Head of Pharma Development.
From 2001-2004, he served in roles of increasing importance at
Pfizer, ultimately as Senior Director, Clinical Sciences / Clinical
Exploratory Head – Inflammation. From 1983-1991, Wright was a
postdoctoral fellow, Instructor and Assistant Professor at the
Johns Hopkins University School of Medicine. From 1991-2001,
Wright was Assistant Professor, Associate Professor with tenure,
Chief of Rheumatology and Clinical Immunology, and Director of the
UPMC Arthritis Institute at the University of Pittsburgh. He
earned an M.D. from the Johns Hopkins University-School of
Medicine.
Craig A. Tooman has served as President, CEO and Board Director
at Aratana Therapeutics Inc. (NASDAQ: PETX) since January 2019,
following his 6-year tenure as CFO. Craig has decades of executive
level experience and a strong résumé of operational expertise,
including in pet therapeutics and the broader pharmaceutical
industry. He played a vital role in successfully completing
Aratana's initial public offering and has raised more than $5B in
the course of his career. Craig has built strong business
relationships and a successful track record in executive leadership
roles for several pharmaceutical companies, including as CEO of
Avanzar Medical, Inc. and CFO for Enzon Pharmaceuticals and Ikaria
Inc. He's also held key executive roles at ILEX Oncology, Inc. and
Pharmacia Corporation. Craig earned an M.B.A. in Finance from the
University of Chicago and a B.A. in Economics from Kalamazoo
College.
About CureVac AG
CureVac is a leading company in the field of messenger RNA
(mRNA) technology with more than 19 years’ expertise in handling
and optimizing this versatile molecule for medical purposes. The
principle of CureVac's proprietary technology is the use of mRNA as
a data carrier to instruct the human body to produce its own
proteins capable of fighting a wide range of diseases. The company
applies its technologies for the development of cancer therapies,
antibody therapies, the treatment of rare diseases, and
prophylactic vaccines. To date, CureVac has received approximately
$420 million (€400 million) in equity investments, including
significant investments from SAP founder Dietmar Hopp’s dievini and
the Bill & Melinda Gates Foundation. CureVac has also entered
into collaborations with multinational corporations and
organizations, including Boehringer Ingelheim, Eli Lilly & Co,
CRISPR Therapeutics, the Bill & Melinda Gates Foundation, and
others.
For more information, please visit www.curevac.com or follow us
on Twitter at @CureVacAG.
Media Contact
Jenn Gordon, Media RelationsGlobal Health PR, New York, United
StatesT: +1 202-587-2580jgordon@globalhealthpr.com
Investor Contact
Matthew Beck, Vice President Investor RelationsCureVac AG,
Boston, MA, United StatesT: +1
917-415-1750matthew.beck@curevac.com
Grafico Azioni ARATANA THERAPEUTICS, INC. (NASDAQ:PETX)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni ARATANA THERAPEUTICS, INC. (NASDAQ:PETX)
Storico
Da Giu 2023 a Giu 2024